The presence of a FLT3 gene mutation was the major indicator of a response to CA4948, S63845, and PU-H71 treatment, with elevated susceptibility of AML cells with the FLT3 gene mutation at an allelic ratio >0.5 (Figure 6A). This evidence concerns the gene FLT3 and acute myeloid leukemia.